Fate Therapeutics (FATE) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Fate Therapeutics (FATE) PT Lowered to $8 at Jefferies
March 6, 2025 5:19 AM ESTJefferies analyst Michael Yee lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $8.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "FATE has a new CEO and has presented initial promising data at ASH (1 remission so far) and has emphasized... More
